Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with C...(d in the New England Journal of Medicine...),Health

Date:9/3/2008

d in the New England Journal of Medicine in November 2007 (Vol. 357 No.20), compared prasugrel with clopidogrel (Plavix(R)/Iscover(R)) in patients with ACS undergoing PCI. In the primary analysis of the trial, prasugrel reduced the risk of the composite of cardiovascular death, heart attack or stroke by 19 percent, with an increased risk of major bleeding compared with clopidogrel (2.4 percent vs. 1.8 percent).(2)

Heart attacks are a major manifestation of coronary heart disease, a global health problem. About 7.2 million people die each year from coronary heart disease worldwide.(3) In the United States, the annual rate of heart attack is 920,000, with 600,000 being first-time attacks and 320,000 repeat attacks.(4)

"In this new sub-analysis of TRITON-TIMI 38, we found that the reduction of heart attacks seen with prasugrel compared with clopidogrel was consistent across the spectrum of heart attacks based on type, timing and magnitude," said David Morrow, M.D., M.P.H., associate professor of medicine at Harvard Medical School and the Brigham and Women's Hospital, Boston, USA, and investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group.

About TRITON-TIMI 38

TRITON-TIMI 38 was a Phase III, randomized, double-blind, head-to-head clinical trial comparing the effects of prasugrel versus clopidogrel in patients with ACS who were managed with PCI, a procedure to open blockages in heart arteries including the use of coronary stenting. The study enrolled 13,608 patients at 707 trial sites in 30 countries.

The primary endpoint of the study was to compare the effects of prasugrel to clopidogrel on the combined incidence of cardiovascular death, non-fatal heart attack and non-fatal stroke during a median period of at least 12 months following PCI. Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the approved loading dose of clopidogrel 300 mg anytime be
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. TRITON-TIMI 38 Stent Analysis Favors Prasugrel
5. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
8. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
9. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
10. New Study: Pine Bark Significantly Reduces Menstrual Pain
11. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome